Press Releases
  Date Title View
Rockville, MD, January 6, 2012 — Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million. The sale of its TCD Royalty Subsidiary, which was established in April 2008 to securitize royalties that were generated by Sanctura XR® and Or...
Posted: Jan 6, 2012
Rockville, MD, November 28, 2011 — today announced the initiation of a Phase IIb U.S. clinical trial of its product candidate SPN-810 in the treatment of impulsive aggression in the setting of ADHD. The study is a multi-center randomized, double-blind, placebo controlled clinical trial in children 6 to 12 diagnos...
Posted: Nov 28, 2011
Rockville, MD, March 11, 2011 – Supernus Pharmaceuticals, Inc. today announced that its Phase IIa U.S. clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability, and showed statistically significant median reductio...
Posted: Mar 11, 2011
Rockville, MD, July 13, 2010 – Supernus Pharmaceuticals Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN812 for the treatment of ADHD in adults. The trial is a proof-of-concept, randomized, double-blind, placebo-controlled study in healthy adults aged 18 to 64, i...
Posted: Jul 13, 2010
Rockville, MD, January 27, 2010 – Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus basel...
Posted: Jan 27, 2010
Rockville, MD, July 28, 2009 — Supernus Pharmaceuticals, Inc. today announced that it recently closed a second non-dilutive financing transaction that brings the total funds raised to date against royalties from its partnered products to more than $110 million. In April 2008, the company announced a $75 million t...
Posted: Jul 28, 2009
Rockville, MD., January 30, 2009 — Supernus Pharmaceuticals Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN810 in the treatment of serious conduct problems in the setting of ADHD. The trial is a proof-of-concept, open-label study with pediatric subjects randomiz...
Posted: Jan 30, 2009
Rockville, MD., December 17, 2008 — Supernus Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase III clinical trial for its lead product SPN-804. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of SPN-804 for the adjunctive treatment o...
Posted: Dec 17, 2008
Rockville, MD, April 23, 2008 — Supernus Pharmaceuticals, Inc. today announced that it closed a private placement to institutional investors of $75 million in aggregate principal amount of non-convertible, non-recourse promissory notes. The notes are secured by royalties generated from sales of Oracea®...
Posted: Apr 23, 2008
September 19, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Allergan, Inc. (NYSE: AGN), through its acquisition of Esprit Pharma, has obtained the United States rights to Sanctura® and Sanctura® XR. CONTACT: Russell "Rip" Wilson Chief Financial Officer Supe...
Posted: Sep 19, 2007
FirstPrevious
...
15
NextLast
= add release to Briefcase